Literature DB >> 22077849

A new era in secondary prevention after acute coronary syndrome.

Matthew T Roe, E Magnus Ohman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22077849     DOI： 10.1056/NEJMe1112770

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

Review 1.  Therapeutic approaches to patients with hypereosinophilic syndromes.

Authors:  Hans-Uwe Simon; Amy Klion
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

2.  [Rivarobaxan for patients with recent acute coronary syndrome : ATLAS ACS 2-TIMI 51].

Authors:  N Frey; S Nitschmann
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

Review 3.  Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease.

Authors:  Hyun-Jae Kang; Matthew T Roe
Journal:  J Cardiovasc Transl Res       Date:  2014-01-25       Impact factor: 4.132

Review 4.  Oral factor Xa inhibitors for the long-term management of ACS.

Authors:  James W Wisler; Richard C Becker
Journal:  Nat Rev Cardiol       Date:  2012-02-21       Impact factor: 32.419

Review 5.  Hematopoiesis and Cardiovascular Disease.

Authors:  Wolfram C Poller; Matthias Nahrendorf; Filip K Swirski
Journal:  Circ Res       Date:  2020-04-09       Impact factor: 17.367

6.  Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin.

Authors:  Ping Zhang; András Gruber; Shogo Kasuda; Carey Kimmelstiel; Katie O'Callaghan; Daniel H Cox; Andrew Bohm; James D Baleja; Lidija Covic; Athan Kuliopulos
Journal:  Circulation       Date:  2012-06-15       Impact factor: 29.690

Review 7.  Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction?

Authors:  Matthias Nahrendorf; Filip K Swirski
Journal:  Eur Heart J       Date:  2015-09-08       Impact factor: 29.983

Review 8.  Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis.

Authors:  Alexander C Fanaroff; Vic Hasselblad; Matthew T Roe; Deepak L Bhatt; Stefan K James; Ph Gabriel Steg; C Michael Gibson; E Magnus Ohman
Journal:  Int J Cardiol       Date:  2017-03-14       Impact factor: 4.164

9.  Neuropeptide Y attenuates cardiac remodeling and deterioration of function following myocardial infarction.

Authors:  Yu-Yan Qin; Xiao-Ru Huang; Jian Zhang; Wenjing Wu; Junzhe Chen; Song Wan; Xi-Yong Yu; Hui-Yao Lan
Journal:  Mol Ther       Date:  2021-10-08       Impact factor: 11.454

Review 10.  Rivaroxaban: a review of its use in acute coronary syndromes.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.